DENVER—Cleerly, a pioneer in AI-driven cardiovascular imaging, unveiled new late-breaking research at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans, Louisiana. The findings, drawn from the international CONFIRM2 Registry, highlight the superior performance of Cleerly’s AI-powered atherosclerosis quantification compared to traditional risk assessment methods. The study, titled "Risk stratification by AI-guided CT atherosclerosis quantification according to the clinical likelihood of obstructive stenosis," evaluated data from 6,550 patients—51.6% of whom were female—with a mean age of 59, followed for an average of 4.4 years. The research focused on how AI analysis of coronary CT scans could more accurately predict cardiovascular events by quantifying atherosclerotic plaque burden and identifying the presence and severity of obstructive coronary artery disease. Results showed that Cleerly’s AI system significantly outperformed conventional risk scores such as the Pooled Cohort Equations (PCE) and the American College of Cardiology/American Heart Association (ACC/AHA) risk calculator. Patients classified as high-risk by the AI model had a substantially higher incidence of major adverse cardiac events (MACE), including heart attack, stroke, and cardiovascular death, compared to those classified as low-risk. Importantly, the AI model was particularly effective in reclassifying patients who were deemed low- or intermediate-risk by traditional methods but were found to have significant atherosclerotic disease on imaging. This ability to detect hidden disease early could lead to earlier interventions and improved outcomes. Cleerly’s technology uses deep learning algorithms trained on millions of anonymized cardiac CT scans to automatically analyze plaque volume, composition, and distribution. By transforming complex imaging data into actionable clinical insights, the platform enables clinicians to make more precise risk assessments and personalized treatment decisions. The findings reinforce the growing role of artificial intelligence in preventive cardiology and highlight a shift toward data-driven, image-based risk stratification. As cardiovascular disease remains the leading cause of death globally, tools like Cleerly’s offer a powerful way to identify at-risk individuals before clinical events occur. The presentation at AHA 2025 underscores the potential of AI to transform cardiovascular care, not just in high-risk populations, but across broader, more diverse patient groups. With growing evidence of its accuracy and clinical utility, Cleerly’s AI platform is poised to become a key component in the next generation of heart health management.